On February 12, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported its interim results for the third quarter of 2025 and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The fourth quarter of 2025 was marked by continued execution on our strategy, focusing on advancing mitazalimab towards initiation of registrational trials, strengthening the scientific foundation of our pipeline, and increasing financial flexibility. While the external funding environment for biotech remains challenging, we have concentrated on areas within our control — generating high-quality data, maintaining operational discipline, and making focused investments that position the company to progress mitazalimab toward late-stage development."
Søren Bregenholt, CEO of Alligator Bioscience
BUSINESS UPDATE
Mitazalimab

Scientific validation: Biomarker analyses from OPTIMIZE-1 were published in Cell Reports Medicine, deepening the understanding of mitazalimab’s mechanism of action and links to clinical outcomes.
Additional clinical publication: Data from the Phase 1 REACtiVe-2 study were published in Nature Communications, supporting mitazalimab’s ability to activate systemic immune responses in metastatic pancreatic cancer.
External visibility: Mitazalimab data were presented at international scientific congresses during the quarter, further strengthening clinical relevance and scientific recognition.
ATOR-4066

Pipeline progress: Preclinical and mechanistic data for ATOR-4066 were presented at international scientific meetings, supporting its immune-modulating potential as a next-generation bispecific antibody program.
Strengthened intellectual property: A U.S. patent covering ATOR-4066 was granted, reinforcing long-term protection and supporting the program’s future value.
HLX22

Program expansion: Henlius received approval to initiate Phase 2/3 studies in breast cancer in China, broadening the clinical scope of HLX22 and potentially increasing the opportunity for future milestone payments and royalty revenues for Alligator.
Company / Financial position

Rights issue completed: Alligator finalized a rights issue of units (shares and warrants) to strengthen its financial position and support continued development of mitazalimab.
Outcome announced 22 December: The issue was subscribed to approximately 64.8%, providing around SEK 91 million (gross) before issue costs and repayments.
Additional capital potential in 2026: The rights issue included warrants that may provide further funding next year, supporting continued flexibility.
Bridge financing and loan repayment: The rights issue followed bridge financing to secure near-term liquidity and enabled repayment of bridge loans and part of the outstanding loan to Fenja Capital.
FINANCIAL SUMMARY FOR Q4 AND YEAR-END 2025
The financial summaries for the quarterly periods ending 31 December 2025 and 31 December 2024 are presented below.

All amounts in MSEK,
unless specified October – December 2025 October – December
2024
Net sales - 41.8
Operating profit/loss -22.5 -60.1
Profit/loss for the period -29.0 -55.4
Cash flow for the period 37.2 17.1
Cash and cash equivalents 62.2 64.3
Earnings per share before and after dilution*, SEK -0.66 -73.10
* Adjusted for reverse share split.
The financial summaries for the year-to-date periods ending 31 December 2025 and 31 December 2024 are presented below.

All amounts in MSEK,
unless specified January – December
2025 January – December
2024
Net sales 0.5 57.8
Operating profit/loss -105.8 -229.1
Profit/loss for the period -51.4 -233.9
Cash flow for the period -1.2 -1.2
Cash and cash equivalents 62.2 64.3
Earnings per share before and after dilution*, SEK -1.87 -318.53
* Adjusted for reverse share split.
The full report is attached as a PDF, and is also available on the company’s website: View Source

Alligator will host a webinar on Thursday, 12 February 2026, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, which will be followed by a Q&A session.

(Press release, Alligator Bioscience, FEB 12, 2026, View Source [SID1234662631])